INDP · Indaptus Therapeutics, Inc.
$1.82
+0.09 (+5.20%)
At close · Jul 29
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We have identified conditions and events that raise substantial doubt regarding our ability to continue as going concern.”View the 10-Q filed May 15, 2026
Market Cap
$206.10M
Shares
113.24M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$20.85M
-38.8%
FY2025
Diluted EPS
-$21.58
+52%
FY2025
Operating Cash Flow
-$14.82M
-20.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $7.02M | $9.34M | $7.25M | $7.62M | $6.32M | $2.52M | $2.66M | |
| $10.4M | $10.49M | $8.11M | $8.76M | $8.59M | $5.21M | $944.25K | |
| $17.42M | $19.83M | $15.37M | $16.38M | $14.91M | $7.73M | $3.6M | |
| -$17.42M | -$19.83M | -$15.37M | -$16.38M | -$14.91M | -$7.73M | -$3.6M | |
| — | — | $343.72K | $955K | $588.11K | $17.72K | $15.11K | |
| — | -$20.85M | -$15.02M | — | — | — | — | |
| — | $1716 | $1700 | $2450 | $30 | $1650 | $800 | |
| -$18.86M | -$20.85M | -$15.02M | -$15.42M | -$14.32M | -$7.71M | -$3.58M | |
| — | — | -$15.02M | -$15.52M | -$14.23M | -$7.71M | — | |
| USD/shares | — | -$21.58 | -$44.96 | -$51.24 | -$48.44 | -$52.92 | — |
| USD/shares | — | -$21.58 | -$44.96 | -$51.24 | -$48.44 | — | — |
| shares | — | 966.12K | 334.13K | 300.04K | 295.08K | 146.09K | 69.45K |
| shares | — | 966.12K | 334.13K | 300.04K | 295.08K | 146.09K | 69.45K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.62×
EV/EBIT
—
Peer median 12.32×
P/E (TTM)
—
Peer median 5.17×
Peer medians compare against the 307 similar-size Biotechnology companies (of 522 listed).